Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens

Title: Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens
Authors: Kelly, Jennifer L.; Toothaker, Stephen R.; Ciminello, Lauren; Hoelzer, Dieter; Holte, Harald; LaCasce, Ann S.; Mead, Graham; Thomas, Deborah; Van Imhoff, Gustaaf W.; Kahl, Brad S.; Cheson, Bruce D.; Magrath, Ian T.; Fisher, Richard I.; Friedberg, Jonathan W.
Source: Kelly, J L, Toothaker, S R, Ciminello, L, Hoelzer, D, Holte, H, LaCasce, A S, Mead, G, Thomas, D, Van Imhoff, G W, Kahl, B S, Cheson, B D, Magrath, I T, Fisher, R I & Friedberg, J W 2009, 'Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens', Clinical lymphoma & myeloma, vol. 9, no. 4, pp. 307-310. https://doi.org/10.3816/CLM.2009.n.060
Publication Year: 2009
Collection: University of Groningen research database
Subject Terms: HIV-negative acute lymphocytic leukemia; Non-Hodgkin lymphoma; Non-Hodgkin's lymphoma; Older patients; ACUTE-LYMPHOBLASTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; ADULT BURKITT; CELL LYMPHOMA; HYPER-CVAD; PLUS RITUXIMAB; ADOLESCENTS; CHILDREN; THERAPY; TRIAL
Description: Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.
Document Type: article in journal/newspaper
Language: English
ISSN: 1557-9190
Relation: info:eu-repo/semantics/altIdentifier/wos/000269426800007; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/1d8ae852-a493-4a96-b5bf-d821eee16126; info:eu-repo/semantics/altIdentifier/pissn/1557-9190
DOI: 10.3816/CLM.2009.n.060
Availability: https://hdl.handle.net/11370/1d8ae852-a493-4a96-b5bf-d821eee16126; https://research.rug.nl/en/publications/1d8ae852-a493-4a96-b5bf-d821eee16126; https://doi.org/10.3816/CLM.2009.n.060
Rights: info:eu-repo/semantics/restrictedAccess
Accession Number: edsbas.CC048D7F
Database: BASE